Момедерм

Quick links

Choose a section

Quick links to important sections

Advertisements

Момедерм

Advertisements
Advertisements

Overview of Момедерм

Quick Facts

Property Description
Active ingredient Mometasone Furoate
Form Cream, Ointment, Lotion (Topical Preparations)
Pharmacological class Corticosteroid, Glucocorticoid
Common use Symptomatic relief of skin inflammation
Origin Synthetic

What Kind of Medicine is Момедерм and What is its Composition?

Момедерм is a commercial pharmaceutical preparation containing the active ingredient, Mometasone Furoate, which is a powerful synthetic corticosteroid. The compound belongs to the high-level pharmacological class of glucocorticoids and is generally utilized as a single-ingredient product.

The medication is formulated for the dermatological route of administration, appearing as various topical preparations, including cream, ointment, and lotion. Its synthetic origin is key, as the Mometasone Furoate molecule is chemically engineered to optimize its local efficacy when applied to the skin, utilizing an inert base/vehicle to ensure proper delivery.

What is the Pharmacological Type of Mometasone Furoate?

Mometasone Furoate is clinically recognized for its high potency, classifying it as a potent steroid among topical corticosteroids. This classification is based on the compound's strong anti-inflammatory and vasoconstrictive actions, which help reduce both the biological reaction and the visible signs of skin irritation simultaneously.

This high potency means the drug possesses a strong affinity for the glucocorticoid receptor, allowing it to modulate the inflammatory response effectively at the application site.

What is the General Purpose of this Topical Preparation?

The general purpose of Момедерм is to provide immediate, localized symptomatic relief for highly reactive skin conditions. It is indicated for alleviating both the inflammatory and pruritic manifestations (itching) associated with various corticosteroid-responsive dermatoses.

By delivering potent antipruritic and anti-inflammatory effects directly to the skin, the medication serves to quickly control flares, reducing symptoms like swelling, redness, and persistent itching. Its role is strictly confined to localized, effective symptom management.

Regulatory References

  1. Mometasone Furoate FDA Label for Cream
  2. Mometasone Furoate (DB14512) DrugBank
  3. Mometasone Furoate Mechanism of Action
  4. Mometasone Furoate DailyMed Label
  5. Mometasone Furoate Cream Directions
  6. Mometasone Furoate Cream FDA Label
  7. Mometasone Furoate DailyMed Label (Covers Forms)
  8. Mometasone Furoate (DB14512) Potency
  9. Mometasone Furoate Cream Mechanism of Action
  10. Mometasone Furoate Cream Indications and Usage
Advertisements

What side effects are possible with Момедерм?

Possible Side Effects and Safety Information

Момедерм contains mometasone furoate, a topical corticosteroid. The documented safety profile focuses on local reactions at the application site and the rare potential for systemic effects from absorption.

Commonly Documented Adverse Reactions (by Frequency)

Adverse reactions are classified according to incidence rates documented in regulatory safety labels:

Classification Examples of Reactions
Uncommon (ge 1/1,000 to < 1/100) Folliculitis, burning sensation, pruritus (itching).
Very Rare (< 1/10,000) Paresthesia, contact dermatitis, hypopigmentation, hypertrichosis.

Serious Systemic and Site-Specific Risks

While rare with appropriate use, risks associated with systemic absorption of corticosteroids include suppression of the Hypothalamic-Pituitary-Adrenal (HPA) Axis, which can lead to Cushing's syndrome. Other serious, site-specific risks include the development of cataracts or glaucoma if the medicine is applied near the eyes.

Safety-Related Restrictions and Precautions

The medicine is strictly contraindicated (should not be used) in patients with conditions such as rosacea, perioral dermatitis, acne vulgaris, and untreated cutaneous infections (bacterial, viral, fungal). It must not be used in or near the eyes.

Population-Specific Considerations

Pediatric patients (children) are documented as being more susceptible to systemic toxicity, such as HPA axis suppression, due to their higher skin surface area to body mass ratio. Use in this population is therefore subject to regulatory limitations regarding quantity and duration.

Duration/Exposure Patterns

Prolonged or extensive use increases the risk of both local side effects (e.g., skin atrophy, striae) and systemic effects. The use of occlusive dressings generally increases the rate of absorption and is not routinely recommended.

Advertisements

Overdose and Emergency Response

Overdose Manifestations

The official regulatory profile for a potential overdose of Mometasone Furoate topical, such as Момедерм, focuses on the risks associated with excessive or prolonged systemic absorption of the potent steroid. Overexposure may lead to clinical manifestations described in official labeling as hypercorticism, which includes features resembling Cushing’s syndrome, as well as documented signs like hyperglycemia and glucosuria.

The most serious physiological outcome documented in regulatory sources is the potential for reversible suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. Following this suppression, there is a risk of secondary glucocorticosteroid insufficiency if the medication is withdrawn abruptly.

When to Seek Help

Urgent medical consultation is required if any signs of systemic toxicity or suspected HPA axis suppression are noted. Regulatory guidance mandates that if HPA axis suppression is confirmed, an attempt should be made by a healthcare professional to gradually withdraw the drug or reduce the frequency of application. Management procedures are limited to symptomatic and supportive treatment, as no specific antidote is specified in the official labeling.

Official prescribing information notes that pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface area to body mass ratio, a key consideration documented in regulatory warnings.

Advertisements

Therapeutic Uses of Момедерм

The medication is commonly used to help manage symptoms related to inflammatory or irritative states and provides support that helps ease the overall symptom burden. The medication is generally applicable within therapeutic areas involving heightened responses.

Relief of Redness, Swelling, and Inflammation

This domain is used in situations involving certain distressing symptoms, primarily the inflammatory manifestations of conditions like Psoriasis and Atopic Dermatitis (Eczema). It is applied in clinical settings where pronounced redness and localized swelling are present. This supportive therapeutic benefit is commonly used to help address groups of symptoms that may become intense and may assist with managing symptoms that interfere with daily comfort.

The medication is relevant for easing symptoms associated with corticosteroid-responsive dermatoses, including inflammatory signs, intense pruritus (itching), and secondary symptoms like scaling and thickening of the skin patches.

Management of Intense Itching (Pruritus)

The medication is applied in addressing symptoms related to physical discomfort, relevant for easing challenging manifestations such as itching. It is relevant for managing symptoms that interfere with daily comfort. This symptomatic relief supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.

“This application is relevant for managing symptoms that interfere with daily comfort and supports patients during episodes of heightened discomfort.”


Quick Fact: Symptom Domains

Feature Description
Primary Use Symptomatic management of inflammatory skin conditions.
Target Symptoms Redness, swelling, persistent itching, and scaling.
Key Benefit Contributes to easing the overall symptom load during acute episodes.

Regulatory References

  1. NIH DailyMed drug label
Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults: Generally eligible for use under standard labeled conditions.
  • Children ge 2 years: Eligible for use (US labeling) for corticosteroid-responsive dermatoses. Older adults are eligible, though greater sensitivity cannot be ruled out.

Populations for whom use is contraindicated:

  • Hypersensitivity: Patients with a known allergy to mometasone furoate or any other component in the preparation.
  • Skin Infections: Application to areas with untreated bacterial, viral (e.g., herpes simplex), fungal, or parasitic infections.
  • Specific Disorders: Use is contraindicated on facial rosacea, acne vulgaris, perioral dermatitis, napkin eruptions (diaper rash), or on wounds and ulcerated skin.

Age-Related and Conditional Use Restrictions

Age-related eligibility rules:

  • The use in children below 2 years of age is not recommended because safety and efficacy have not been formally established in this age group.
  • Use in children ge 2 years is subject to caution, as they have a higher risk of systemic absorption.

Pregnancy and lactation eligibility status:

  • Pregnancy: Classified as Conditional Use. Should be used only if the potential benefit justifies the potential risk to the fetus.
  • Lactation: Caution should be exercised; it is unknown if topical application results in detectable quantities in human milk.

Eligibility-related restrictions:

  • The medicine must NOT be used under occlusive dressings (e.g., tight bandages, diapers) unless medically supervised.
  • Use on the face, groin, or underarms should be avoided unless specifically directed by a healthcare provider.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for the topical formulation of Момедерм (Mometasone Furoate) primarily addresses interaction risks related to the drug's classification as a potent corticosteroid. The product's profile is structured around its potential for systemic absorption, as dedicated drug-drug interaction studies for the topical route have not been conducted according to the FDA prescribing information. Consequently, no specific interactions mediated by Cytochrome P450 enzymes or drug transporters are documented in the regulatory labels.

Documented Interaction Patterns

Interaction Type Official Regulatory Statement
Pharmacodynamic Risk Co-administration with other corticosteroid-containing products (topical or systemic) creates a risk of additive systemic glucocorticoid effects.
Exposure Outcome This pharmacodynamic interaction can lead to increased systemic corticosteroid exposure, which is clinically represented by the risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

Population-Specific Interaction Notes

Certain patient factors are identified as increasing the risk of systemic interaction consequences. Liver failure is listed as a condition that predisposes a patient to HPA axis suppression due to altered clearance. Similarly, pediatric patients are noted to be more susceptible to systemic toxicity from equivalent doses due to a larger skin surface-to-body mass ratio, increasing the potential for adverse systemic interaction outcomes.

Advertisements

Mechanism of Action

Genomic Regulation via the Glucocorticoid Receptor

Момедерм acts as an agonist for the Glucocorticoid Receptor (GR) inside skin cells, a key regulatory target that modulates gene activity. The drug-receptor complex enters the cell nucleus to initiate transrepression (silencing pro-inflammatory genes) and transactivation (activating anti-inflammatory genes, such as those for Lipocortin-1). This action initiates the cellular sequence for modulation of the inflammatory response at the genetic level.

Blocking the Arachidonic Acid Cascade

The resulting increase in Lipocortin-1 directly inhibits the enzyme Phospholipase A2 ( PLA2), which is essential for producing Arachidonic Acid. By blocking this step, the drug stops the formation of major inflammatory mediators, namely Prostaglandins and Leukotrienes. This prevents the chemical signaling that facilitates localized tissue edema and erythema, contributing to modulation within targeted pathways.

Vascular Tone Modulation and Anti-Pruritic Consequence

The suppression of these vasodilatory mediators (Prostaglandins) leads to localized narrowing of blood vessels (vasoconstriction) and decreased fluid leakage from capillaries. This mechanism causes the physiological adjustments of localized vasoconstriction and decreased capillary permeability, initiating the neural suppression associated with the antipruritic consequence.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Mometasone Furoate

All forms of Момедерм (Mometasone Furoate topical preparations) are administered by the topical route only and are not approved for ophthalmic use. The dosage forms available are the cream, ointment, and lotion, all at a concentration of 0.1% (w/w).

The standard dosing regimen for adults and children two years of age and older (12 years for the lotion) is application once daily (qDay). For the cream and ointment, a thin film should be applied to the affected area. The lotion requires a few drops to be applied and massaged lightly until it disappears.

The official protocol mandates that treatment should be discontinued promptly once the condition is under control. If there is no documented improvement within two weeks, a reassessment of the patient’s condition is necessary.

Special Procedural Conditions and Limits

The label specifies constraints to ensure proper use. The preparations should not be used with occlusive dressings, such as bandages or plastic pants (like diapers), unless specifically directed by a prescriber. Application to sensitive areas like the face, groin, or axillae should generally be avoided. For the face, treatment courses are typically restricted to a maximum of five days. Hands should be washed after each application, except when the hands are the area being treated.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Момедерм


Evidence for Use in Atopic Dermatitis (Eczema)

The research for topical mometasone furoate was evaluated in populations with atopic dermatitis, a condition characterized by fluctuating or episodic manifestations, and consists primarily of short-term randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the medicine to an inactive vehicle (placebo) or to other active comparator treatments. These trials applied in studies examining patient-reported experiences and included populations of Adults, Adolescents, and Children presenting with conditions involving periods of heightened symptoms.

Studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states. Research highlights changes measured during the study period, with findings describing patterns observed in specialized medical scores, such as the SCORAD index and the Physician's Global Assessment (PGA), over defined observation periods, typically lasting a few weeks.


Evidence for Use in Psoriasis Vulgaris

Topical mometasone furoate was studied in populations with plaque-type psoriasis, a condition where symptoms may vary in intensity. The main research evidence is derived from short-term Randomized Controlled Trials (RCTs). The studies monitored patient-reported outcomes describing perceived discomfort by using objective measures like the Psoriasis Area and Severity Index (PASI). Research explored short-term symptom changes, with data describing patterns related to the reported state of the skin based on the PGA scores after several weeks of observation.


Long-Term Studies and Follow-Up Data

Most of the high-quality, placebo-controlled evidence is relevant in trials assessing short-term or episodic symptom patterns, typically lasting only a few weeks. While some open-label and follow-up studies have monitored outcomes for up to 6 to 12 months, the data available for consistent, long-term outcomes related to durability of response remains limited.

The research provides context but not individual predictions for the long-term. Findings describe group patterns, not personal outcomes, and evidence for the consistent persistence of effect over extended periods is still emerging.


What is Still Uncertain About Момедерм's Research Base

The existing body of research, while extensive, highlights areas where certainty remains low. The results apply only to the populations studied, meaning that findings describe group patterns, and outcomes for individuals may vary. Specifically:

  • Long-term effects are not fully established, particularly for continuous use or maintenance strategies beyond 3–6 months.
  • Data for certain groups remain insufficient, especially regarding the long-term symptom management in infants under two years of age.

Key Studies & References

  1. MOMETASONE FUROATE cream, for topical use (Official FDA/DailyMed Label)
  2. Frequency of application of topical corticosteroids for atopic eczema (NICE Guideline/Evidence Review)
  3. Efficacy of Topical Mometasone Furoate 0.1% Cream in the Treatment of Atopic Dermatitis (Representative Clinical Trial)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Момедерм (FAQ)


Q: How quickly should I expect to see an effect from Момедерм?

Official guidelines for this medication do not provide a set timeline for initial symptom relief. However, regulatory documents state that if improvement in the condition is not observed within two weeks of use, a reassessment of the diagnosis is necessary. This two-week mark is used as a formal benchmark for evaluating treatment progress.


Q: Can Момедерм be used on the face?

Official patient safety information indicates that use of this topical preparation on sensitive areas of the body, including the face, is generally restricted or not recommended. Application to the underarms or groin areas should also be avoided. This precaution is noted because these areas are more susceptible to the side effects associated with topical corticosteroids.


Q: What does it mean if the skin condition seems to worsen after starting Момедерм?

A worsening of the treated skin condition may signal a complication. Regulatory documentation indicates this could be a sign of a secondary issue, such as an allergic reaction (contact dermatitis) to the product itself, or an untreated skin infection. If the condition appears to worsen after starting the medicine, these changes should be reported to a healthcare provider.


Q: What are the most serious side effects that have been reported with Момедерм?

The most serious, though rare, safety risks documented are related to systemic absorption of the steroid. These risks include the suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis, which affects the body’s natural steroid production. Additionally, if the medicine is used near the eyes, the risk of developing cataracts or glaucoma is increased.


Q: Is it normal to experience mild redness when first applying Момедерм?

According to information from regulatory sources, some individuals may experience common local adverse reactions at the application site. These reactions include transient burning, itching, irritation, and redness of the skin. These effects are often transient.


Q: Is Момедерм the same as other 'mometasone' products I see?

Момедерм is a brand name for a product containing the active ingredient Mometasone Furoate. This same active compound may be found in other products, including other topical creams or different drug forms like nasal sprays, which may be sold under various brand names for related or different medical uses.


Q: Can Момедерм be used for everyday dry skin?

The official indication for this medicine is for the relief of inflammation and itching related to specific corticosteroid-responsive dermatoses (skin conditions). The product is not generally intended for non-clinical, general skincare use, such as the routine treatment of everyday dry skin.


Q: Does Момедерм help with itching?

Yes, official regulatory labeling states that the medicine is indicated for the relief of pruritic manifestations, which means it is designed to help control the itching associated with certain skin conditions.


Q: Why do some people say they felt a burning sensation when starting Момедерм?

A burning sensation is documented as a common local adverse reaction that may be felt immediately upon application. This effect is usually temporary, lasting only a few minutes, and may resolve after the first few days of use.


Q: Are there different strengths of Момедерм available?

The topical formulations of this medicine (the cream, ointment, and lotion forms) are generally available at a standard concentration of 0.1% of the active ingredient, according to regulatory documents.


Q: Can Момедерм cause changes in skin pigmentation?

Yes, official regulatory safety data notes that changes in skin color, specifically hypopigmentation (lighter patches of skin), have been reported. This effect is considered a local adverse reaction linked to the use of potent topical corticosteroids.


Q: Is Момедерм available over the counter, or is it prescription-only?

The topical formulation of Mometasone Furoate is generally classified as a prescription-only medicine across most regulatory authorities, including in the US and the European Union.


Q: Is Момедерм absorbed into the bloodstream?

Yes, official regulatory documentation confirms that topical corticosteroids can be absorbed through the skin and enter the bloodstream. This systemic absorption is the reason for the potential, although rare, risk of effects on the adrenal glands.


Q: Do experts recommend taking breaks from using Момедерм?

The regulatory protocol is to discontinue therapy promptly once the condition is under control, rather than continuing use indefinitely. Long-term continuous use is associated with an increased risk of adverse effects, including potential withdrawal reactions if stopped suddenly after prolonged application.


Q: How is the mechanism of action of Момедерм described in simple terms?

In simple terms, this medicine belongs to the group of corticosteroids, which are powerful anti-inflammatory agents. It works by acting on cells in the skin to activate natural substances that help reduce the key symptoms of swelling, redness, and itching.


Q: Can people with diabetes use Момедерм without additional concerns?

Since the medicine can be absorbed into the body, there is a theoretical, rare risk of systemic effects that may result in hyperglycemia, or high blood sugar. Notification of this possibility is provided for individuals with diabetes in regulatory documents regarding systemic risks.


Q: Does Момедерм interact with any herbal supplements?

Specific drug-drug interaction studies focused on the topical form are generally not available. Regulatory authorities indicate there is usually not enough information to definitively state whether herbal remedies and dietary supplements are safe to take with topical Mometasone Furoate.


Q: Are there restrictions on the total body surface area that can be treated with Момедерм?

While no universal percentage limit is cited, official labeling includes a warning that applying a topical steroid to a very large surface area of the body increases the potential for systemic absorption. This increased absorption raises the risk of related side effects like HPA axis suppression.


Q: What should be done if Момедерм is accidentally ingested?

This medication is strictly intended for topical application and should not be swallowed. Official safety protocol is that if accidental ingestion or application to the mouth occurs, advice from a healthcare professional be sought.


Q: Is it okay to stop using Момедерм suddenly?

Official sources note that following prolonged or frequent use, stopping the medicine suddenly may increase the risk of potential rebound effects or withdrawal reactions. A gradual reduction under the guidance of a healthcare provider may be warranted to help manage this risk.


Q: What is the difference between Момедерм and hydrocortisone?

Regulatory classifications place Момедерм (Mometasone Furoate) as a more potent topical steroid compared to milder options, such as hydrocortisone. This difference in potency means they are typically prescribed for different severities of skin conditions.


Q: Are there reports of people developing tolerance to Момедерм over time?

Yes, official regulatory and dermatological sources describe a reduced response to the medication with continued and prolonged use, a phenomenon sometimes called tachyphylaxis. This may be a consideration for long-term treatment plans.


Q: Has there been research comparing Момедерм to a placebo?

Yes, the research evidence supporting the use of this medicine for conditions like atopic dermatitis and psoriasis includes short-term randomized controlled trials. These trials compared the medicine's effects against an inactive vehicle, or placebo.


Q: Does Момедерм contain any preservatives or inactive ingredients that can cause irritation?

Official product information states that the medicine is strictly contraindicated for patients with a known history of hypersensitivity. This includes an allergic reaction to any component of the preparation, encompassing both the active ingredient and any inactive ingredients used in the formulation.


Q: Is the absorption rate of Момедерм affected by damaged skin?

Yes, systemic absorption can be increased when the skin barrier is compromised. For this reason, official safety information warns against applying the product to wounds, ulcerated, or damaged skin, as this raises the potential for systemic effects on the body.


Q: Can Момедерм be used around the eyes?

Official safety documentation advises against use around the eyes. The product is strictly for topical use on the skin, and use near the eyes carries a risk of ophthalmic side effects, such as developing cataracts or glaucoma.

Advertisements

How should Момедерм be stored and disposed of?

The official regulatory profile for Mometasone Furoate (Момедерм) mandates specific storage and disposal conditions to maintain product quality.

Required Storage and Handling

The medication must be stored at controlled room temperature, typically 20 C to 25 C. It is required to be kept in its original container, which must be tightly closed. The product must be protected from freezing and stored away from excessive moisture. For nasal spray formulations, the container must be discarded after two months following the first use. All preparations must be stored out of the sight and reach of children.

Official Disposal Rules

Unused or expired medicine must be disposed of according to local regulatory requirements. It is explicitly required that the product not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Момедерм found in:

A-Z Index: